Who are R-DA-EPOCH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Venetoclax; Rituximab, Columvi, Lunsumio, Ocrevus, Gazyva, Kesimpta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/r-da-epoch.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

R-DA-EPOCH — Competitive Intelligence Brief

R-DA-EPOCH (R-DA-EPOCH) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + chemotherapy combination. Area: Oncology.

phase 3 Monoclonal antibody + chemotherapy combination CD20 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R-DA-EPOCH (R-DA-EPOCH) — Fujian Medical University. R-DA-EPOCH is a rituximab-based chemotherapy regimen that combines the anti-CD20 monoclonal antibody rituximab with dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, and doxorubicin (daunorubicin) to treat lymphoid malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
R-DA-EPOCH TARGET	R-DA-EPOCH	Fujian Medical University	phase 3	Monoclonal antibody + chemotherapy combination	CD20
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Columvi	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Kesimpta	OFATUMUMAB	Novartis	marketed	Anti-CD20 monoclonal antibody	CD20	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + chemotherapy combination class)

Fujian Medical University · 2 drugs in this class
Shandong Provincial Hospital · 2 drugs in this class
The Lymphoma Academic Research Organisation · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class
Nordic Lymphoma Group · 1 drug in this class
Prof. Dr. M. Dreyling (co-chairman) · 1 drug in this class
American Scitech International · 1 drug in this class
Universität des Saarlandes · 1 drug in this class
AryoGen Pharmed Co. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R-DA-EPOCH — Competitive Intelligence Brief. https://druglandscape.com/ci/r-da-epoch. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab